() chief executive Tim Mitchell caught up with Proactive London's Andrew Scott to discuss some preliminary efficacy data released on a drug that Sareum helped to develop.
Of particular note was the impact SRA737 had in combination with a common chemotherapy called gemcitabine in patients with anogenital cancer ... ''the trial's been very, very successful indeed'', Mitchell says.
The data's been taken from a phase I/II clinical trial undertaken by , which licensed the drug candidate in a deal worth up to US$328.5mln plus royalties.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Sareum Holdings PLC named herein, including the promotion by the Company of Sareum Holdings PLC in any Content on the Site, the Company...
FOR OUR FULL DISCLAIMER CLICK HERE